EcoNaviSta, Inc. has announced its board’s decision to support and recommend a tender offer by Eisai Co., Ltd. for its shares, which aims to make EcoNaviSta a wholly-owned subsidiary of Eisai. This ...

Japanese drugmaker Eisai Inc. will lay off 57 employees in Nutley between the end of March and May, public records show, as the pharmaceutical company shaves off 7% of its U.S. workforce. The New ...

The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's ...

Eisai’s cuts will affect 121 employees across the Japanese company’s U.S. operations, including 57 people at its American ...

TOKYO -- Japanese drugmaker Eisai's share price is hovering around a 10-year low of 4,300 yen, weighed down by poor U.S.

Along with Nutley-based Eisai, several other New Jersey-based giants in the space have conducted layoffs over the past few months, including Bristol Myers Squibb, Bayer and Johnson & Johnson.

Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...

Eisai (ESAIY) and Biogen (BIIB) announced that the Therapeutic Goods Administration, TGA, of Australia has confirmed the initial decision to ...

Just on that basis as well, Eisai seems to us undervalued. Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks ...

HHS Secretary Robert F. Kennedy Jr. is proposing to strip public participation from much of the business his agency conducts ...

Eisai (ESAIY) and Biogen (BIIB) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has ...

England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...